Follow us
Our Mission
In the battle against cancer, BIODENA CARE considers its mission as a succession of relays between Fundamental Scientific Knowledge on the one hand and "the Art and Science of Medicine" on the other.
The final relay, undoubtedly the most important, is the one that the Physician must carry out alone with his Patient, against the disease.
This is why, in order to never forget the Patient, we carry out our mission by exclusively serving Physicians with a single objective:
« To ensure that demonstrations of basic science become effective, reliable and accessible solutions, handed over to physicians for the benefit of their patients. »
The dream of a scientist, the fight of a woman
Dominique Joubert
Senior Scientist Consultant
Dominique Joubert is a scientist with a PhD in biology and over 40 years of experience in academic and fundamental research. Between 1991 and 2011, she served as Director of Research at Inserm (France) and Director of the Oncology Department at the IGF, a Joint Research Unit of CNRS, INSERM, and the University of Montpellier.
Throughout her career, Dominique Joubert has challenged the prevailing scientific dogma by maintaining her belief that cancer follows the "laws of the living" and is therefore reversible. This conviction led her to search for a "key" to this reversion.
In 2003, a groundbreaking observation was made in her lab on a protein that needed to exit the tumor cell and re-interact with it to exert its effect on the tumor. Dominique Joubert hypothesized that this protein, linked to disruptions in the Wnt signaling pathway (a major contributor to tumorigenesis), could be the key to reversing the tumor process.
Her bold approach was met with skepticism. She proposed that neutralizing this protein could regulate the very pathway that produced it—an idea her team found far-fetched. Despite the doubts, Dominique Joubert proceeded with the experiment. To the surprise of many, the results were conclusive, providing the first demonstration that a tumor mechanism could be reversed in solid tumors.
The protein in question is progastrin, the precursor of gastrin, which is found in the G cells of the stomach in healthy individuals and is absent from the bloodstream. However, in cancer patients, progastrin is secreted by tumor cells and is referred to as hPG80. Her research has shown that hPG80 is present in the blood of 83% of cancer patients, and that 100% of tumors produce this protein.
Dominique Joubert believes that this discovery will revolutionize cancer treatment. However, she recognizes the challenges ahead: the need to mobilize the necessary resources, expertise, and energy to ensure that this breakthrough in basic research translates into practical solutions for physicians and ultimately benefits patients.